Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint Inhibitors.

ABSTRACT: Immune checkpoint inhibitors (ICPi) have shown their superiority over conventional therapies to treat some cancers. ICPi are effective against immunogenic tumors. However, patients with tumors poorly infiltrated with immune cells do not respond to ICPi. Combining ICPi with other anticancer therapies such as chemotherapy, radiation, or vaccines, which can stimulate the immune system and recruit antitumor T cells into the tumor bed, may be a relevant strategy to increase the proportion of responding patients. Such an approach still raises the following questions: What are the immunological features modulated by immunogenic therapies that can be critical to ensure not only immediate but also long-lasting tumor protection? How must the combined treatments be administered to the patients to har

SUBMITTER: Dosset M 

PROVIDER: S-EPMC7408477 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature